A 60-year-old man was admitted to our hospital with marked hypercalcemia. He had no symptoms that might be caused by hypercalcemia. Plasma concentrations of calcium and intact parathyroid hormone were 15.2 mg/dl and 103 pg/ml, respectively. Radiological examinations revealed no abnormal findings. His calcium-creatinine clearance ratio was calculated to be 0.004, thus he was diagnosed as having hypocalciuric hypercalcemia. Familial hypocalciuric hypercalcemia was a plausible diagnosis, however, gene analysis of his calcium-sensing receptor (CaSR) revealed no mutation. The patient was thought to be a case of hypocalciuric hypercalcemia without mutation in the CaSR gene.
Introduction
Among patients with hypercalcemia, the frequent causes are primary hyperparathyroidism (PHP) and malignancy-associated hypercalcemia (1, 2) . Patients with these diseases are usually accompanied by thirst, anorexia, nausea and consciousness disturbance, and in general, they have an increased urinary excretion of calcium (Ca). Bycontrast, a rare cause of hypercalcemia without any symptomswas first reported in 1 978 as familial hypocalciuric hypercalcemia (FHH) (3, 4) . Patients with FHHare different from other cases of hypercalcemia, as they show marked hypocalciuria despite increased serum Ca levels. FHHhas been reported to be caused by mutations in the calcium-sensing receptor (CaSR) gene (5, 6) . CaSR is a cellsurface protein that is expressed in the parathyroid gland and kidney, and regulates the serum Ca concentration (5) . In patients with FHH, mutations in the CaSRgene associated with a loss of function lead to an excessive reabsorption of Ca by the renal tubules (6) . In a previous report, about two-thirds of FHH cases are caused by mutations in the CaSRgene (7) . Wetreated a patient who showed marked hypercalcemia and hypocalciuria without a mutation in the CaSRgene. Despite the lack of family history, his clinical feature was similar to that of FHH.
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Case Report
A 60-year-old man had been pointed out to have marked hypercalcemia at his annual health examination, and visited our hospital for further examination. There was no consanguineous marriage amonghis lineage. His plasma concentrations of Ca and intact parathyroid hormone (intact-PTH) were 15.2 mg/dl and 103 pg/ml, respectively, at the first visit. He had no symptoms, which might be considered to be caused by marked hypercalcemia, such as nausea, polyuria, polydipsia, oral thirst, and lethargy. Laboratory findings on admission are listed in was detected in the at 1 and 3 hour post-injection images (Fig.  2) . Ectopic parathyroid glands were not observed by the chest CT or Tc-99m MIBI scintigraphy of the whole body. His electrocardiogram was within normal limits, with no significant shortening of the QTinterval. Ophthalmological examination revealed no abnormal findings in the cornea of the patient. As the clinical features of the patient suggested FHH,we examined serum Ca of his family members (3 of 7 siblings and 2 descendants). As a result, there wasno member with hypercalcemia. Thus, this patient was thought to be an isolated hypocalciuric hypercalcemia.
Analysis of the nucleotide sequence in the CaSRgene was performed with his informed consent, using a previously reported method (8, 9) . Briefly, genomic DNAwas extracted from peripheral leukocytes using QIAamp Blood Kit (Qiagen, Hilden, Germany). All coding exons and exon-intron boundaries were amplified by the polymerase-chain reaction (PCR) using exon-specific primers as templates (8) . The PCRproducts were directly sequenced using PRISMready reaction dye deoxyterminator cycle sequencing kit and ABI model 373S-36 autosequencer (Perkin-Elmer, Chiba). Direct sequencing of the PCRproducts revealed no mutations in any of the coding exons or exon-intron boundaries of the CaSRgene in the patient. In the clinical course, we administered 2,000 ml per day of physiological saline and 80 units of elcatonin per day intravenously, but serum Ca level remained unchanged (Fig. 3) . When 30 mg of pamidronate was injected intravenously, the serum Ca level was subsequently decreased to 13.2 mg/dl. However, up to one month later, the serum Ca level remained increased to 15.2 mg/dl. He has been followed up with no treatment after discharge; to date, he has not suffered from any symptom. Hypocalciuric Hypercalcemia hypercalcemia generally suffer from symptomsassociated with hypercalcemia (for example; weakness, nausea, polyuria, polydipsia) and various complications, and the urinary excretion of Ca is usually high in these patients. By contrast, the present patient revealed asymptomatic hypercalcemia, and he had no complications associated with hypercalcemia, such as pancreatitis, nephrocalcinosis, peptic ulcer and osteitis fibrosa. Imaging examinations including ultrasonography, CT and Tc-99m MIBI scintigraphy revealed no parathyroid tumor nor ectopic parathyroid glands. The reduction of bone density was not observed by radiography. Urinary analysis demonstrated a marked reduction of Ca excretion and the Cca/Ccr was strikingly decreased to 0.004, thus our patient was diagnosed as having hypocalciuric hypercalcemia. Family memberswere also studied, however, 3 of 7 siblings and 2 descendants revealed normal levels of serum Ca; the patient did not have a family history, and was thought to have a possibility of an isolated hypocalciuric hypercalcemia. The clinical features of this patient were quite similar to those of FHH.FHHis characterized by moderate hypercalcemia and inappropriately low Ca excretion into urine; the Cca/ Ccr is usually decreased to <0.01 (2) . Serum Ca concentrations in patients with FHHare usually between 10.5 and 12 mg/dl (2-4), while our patient showed a marked hypercalcemia of 15.2 mg/dl, suggesting that this was a rare case. FHHis generally inherited in an autosomal dominant fashion, and the clinical course of such patients is reported to be generally benign, and rarely accompanied by symptoms and complications associated with hypercalcemia ( 10). Recently, it was reported that FHHis caused by mutations in the CaSR gene, which encodes a cell surface receptor protein that regulates the secretion of parathyroid hormoneand the reabsorption of Ca on the renal tubules in response to alternation in the serum Ca concentration (6, ll) . The CaSR gene was mapped to 3q.l3.3-q21 by fluorescence in situ hybridization (12) , and cloned in 1993 (6) . Mutations of this receptor gene generally lead to a loss of function, resulting in an excessive reabsorption of urinary Ca associated with a cause of FHH(heterozygous mutation) and neonatal severe hyperparathyroidism (NSH) (homozygous mutation) (1 1). Approximately two-thirds of patients with FHHare reported to have a mutation in the CaSR gene (7), and classified as type I familial benign hypercalcemia (FBH). However, another type of FHHwithout involvement of the CaSR gene has also been described (13) . Weinvestigated the nucleotide sequences of the CaSRgene in the patient, but there wasno mutation in the region, thus the patient was thought to be one of such variant without involvement of the CaSRgene.
This patient did not have any nucleotide change in the coding exons and exon-intron boundaries of the CaSR gene and thus the mechanismof marked hypercalcemia in the patient is still unknown. Chikatsu et al reported that the different structures of the promoter of humanCaSRcause changes in the expression of the parathyroid CaSRin parathyroid adenoma (9) . A mutation in the promoter region of the CaSRmay result in a decreased expression of receptor. Another mutation may cause a reduced intracellular transport of the CaSRprotein to the cell surface. Furthermore, post-CaSR intracellular signal transduction followed by G protein system may be involved (14) .
In addition, in the previous linkage analyses, chromosome 19pl3.3 and 19ql3 were also mentioned as candidate loci responsible for FHH (15) (16) (17) It is interesting that the present patient had no symptoms or complications that might be caused by hypercalcemia, despite the continuous markedhypercalcemia of higher than 15 mg/ dl. In general, patients with NSH, caused by homozygous mutation of the CaSR, also have similar marked hypercalcemia, but these cases are accompanied by various complications of hypercalcemia, and NSHis usually thought to be life threatening (1). In our patient, the mechanism causing hypercalcemia may differ from that of FHHand NSH. Weadministered elcatonin and pamidronate for the treatment of hypercalcemia (Fig. 3 ). Elcatonin and bisphosphonate (including pamidronate) both decrease the serum Ca concentration by inhibiting osteoclastic bone reabsorption, but the mechanisms of these drugs are different (18, 19) . Elcatonin inhibits bone reabsorption through the calcitonin receptor ( 1 8).
It acts rapidly but rarely produces a decline in serum Ca of more than 2 mg/dl, and its efficacy is usually limited to a few days at most, possibly because of the receptor down-regulation in target cells of bone and kidney (20) . Onthe other hand, bisphosphonate is rapidly distributed to bone tissue and remains for a long period after administration (19) . Bisphosphonate is released from bone tissue and it specifically inhibits osteoclastic reabsorption (19) . It acts slowly, but its efficacy is stronger than elcatonin (21) . From these reasons, elcatonin had little effect on the serum Ca concentration in this patient, but pamidronate was effective.
For treatment, it is important to distinguish FHHfrom PHP. Parathyroidectomy is often recommendedin patients with PHP, but not in patients with FHH, because parathyroidectomy is usually unsuccessful in FHH (22) . Urinary Ca excretion is generally increased in patients with PHP, while it is markedly decreased in patients with FHH.In cases with asymptomatic hypercalcemia, measurement of urinary Ca should be performed, and a markedly reduced excretion of urinary Ca suggests a diagnosis of hypocalciuric hypercalcemia. In such cases, analysis of mutations in the CaSRgene is recommended.
